Kukje Pharma Co., Ltd.

002720.KS

002720.KSKukje Pharma Co., Ltd. KR flag

KSE

4,610.00

KRW

-95.00

(-2.02%)

93.87BMarket Cap

Mar 31Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

KR7002720001

Return %

Stock

S&P500

-5.24

6.57

-21.42

22.75

-24.73

93.55

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	6,340.35	6,028.89	6,122.47	5,787.59	5,847.79	6,119.12	5,302.96	5,484.16	6,135.62	5,642.65	5,964.52	6,675.99	- -	7,675.19
Basic EPS, GAAP	-947.3	106.36	-346.67	-292.38	37.46	54.2	107.98	-234.96	103.66	-73.47	167.62	-415	- -	255.34
Free Cash Flow per Basic Share	-0.98	-319.32	-122.54	-308.12	649.85	-164.92	482.43	-112.67	-305.83	359.85	246.29	124.73	- -	50.47
Dividend per Share	13.93	- -	7.17	7.27	- -	7.83	8.13	25.42	- -	- -	- -	- -	- -	- -
Book Value per Share	1,714.33	1,885.84	1,507.63	1,167.27	1,162.44	1,223.27	1,227.23	880.17	1,009.76	959.9	1,249.7	876.28	- -	1,303.19
Tangible Book Value per Share	2,714.4	2,867.96	2,505.06	3,330.89	3,204.81	3,224.8	3,290.94	2,925.46	3,247.05	3,169.17	3,437.53	4,144	- -	4,350.05
Basic Weighted Avg Shares	20	20	20	20	21	20	20	20	21	21	21	20	- -	20
Sales/Revenue/Turnover	126,768	120,461	122,426	117,637	120,684	123,310	107,681	111,122	130,395	119,746	126,583	135,373	156,463	156,463
Operating Margin (%)	-11.6	0.87	-1.16	1.78	3.29	2.08	3.05	5.01	4.63	-1.4	4.17	-1.47	4.28	4.28
Depreciation Expense	4,152	4,077	3,780	3,357	2,887	2,642	2,741	3,251	3,626	4,419	4,488	4,204	3,203	3,203
Net Income, GAAP	-18,940	2,125	-6,932	-5,943	773	1,092	2,193	-4,761	2,203	-1,559	3,557	-8,415	5,205	5,205
Effective Tax Rate (%)	- -	- -	- -	- -	54.87	49.4	22.87	4,021.09	60.77	- -	25.34	- -	21.23	21.23
Profit Margin (%)	-14.94	1.76	-5.66	-5.05	0.64	0.89	2.04	-4.28	1.69	-1.3	2.81	-6.22	3.33	3.33
Working Capital	12,629	39,226	16,354	34,521	10,506	8,960	6,360	1,884	-5,417	-6,319	680	-4,568	28,427	28,427
LT Debt	750	24,250	7,000	27,000	2,000	4,000	- -	2,256	3,792	1,620	1,196	476	27,342	27,342
Total Equity	55,352	58,329	50,853	68,459	67,519	67,778	68,698	60,954	70,499	68,588	74,079	84,950	89,548	89,548
Return on Invested Capital (%)	- -	- -	- -	- -	1.72	1.3	2.58	-226.18	2.31	- -	3.88	- -	4.56	4.56
Return on Capital (%)	- -	- -	- -	- -	2.12	2.74	5.12	-71.88	4.36	- -	7.75	- -	11.78	11.78
Return on Common Equity (%)	-43.05	5.91	-20.44	-22.06	3.24	4.49	8.85	-22.27	11.21	-7.45	15.17	-38	23.48	23.48

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	2.88%	7.48%	15.58%
Net Income, GAAP	-144.6%	-228.72%	-161.85%
Free Cash Flow	-98%	-35.72%	-62.63%
Total Cash Common Dividend	- -	- -	- -
Total Equity	6.48%	8.21%	5.41%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Tae-hoon Nam
Full Time Employees: 242
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 96-8, Yatap-ro Seongnam-si South Korea
IPO Date: Sep 29, 2005
Website: kukjepharm.co.kr
Similar Companies: cbdMD, Inc. (YCBD)
PT Merck Tbk (MERK.JK)
FutureWorld Corp. (FWDG)
Shanghai Jiaoda Onlly Co.,Ltd (600530.SS)
Dynavax Technologies Corporation (DVAX)
Ilyang Pharmaceutical Co.,Ltd (007570.KS)
Business: Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, and other ETC products. The company was founded in 1959 and is headquartered in Seongnam, South Korea.

	Jun'24	Sep'24	Dec'24
Total Current Assets	52,491	53,333	56,974
Accounts Receivable, Net	20,335	19,154	22,761
Cash, Cash Equivalents & STI	6,842	8,598	8,755
Inventories	21,720	21,810	22,369
Total Current Liabilities	49,231	23,572	28,547
Payables & Accruals	- -	- -	- -
ST Debt	27,196	2,175	2,170
Deferred Revenue	- -	- -	- -

	Jun'24	Sep'24	Dec'24
ST Debt	27,196	2,175	2,170
LT Borrowings	- -	27,000	27,000
LT Finance Leases	455	381	342
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	20	20	20
Market Capitalization	117,556	110,490	103,151

Year	Q1	Q2	Q3	Q4	FY
2022	105.71	56.19	68.57	- -	167.62
2023	41	-309	-128	- -	-415
2024	135	29	57	- -	- -

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	6,340.35	6,028.89	6,122.47	5,787.59	5,847.79	6,119.12	5,302.96	5,484.16	6,135.62	5,642.65	5,964.52	6,675.99	- -	7,675.19
Basic EPS, GAAP	-947.3	106.36	-346.67	-292.38	37.46	54.2	107.98	-234.96	103.66	-73.47	167.62	-415	- -	255.34
Free Cash Flow per Basic Share	-0.98	-319.32	-122.54	-308.12	649.85	-164.92	482.43	-112.67	-305.83	359.85	246.29	124.73	- -	50.47
Dividend per Share	13.93	- -	7.17	7.27	- -	7.83	8.13	25.42	- -	- -	- -	- -	- -	- -
Book Value per Share	1,714.33	1,885.84	1,507.63	1,167.27	1,162.44	1,223.27	1,227.23	880.17	1,009.76	959.9	1,249.7	876.28	- -	1,303.19
Tangible Book Value per Share	2,714.4	2,867.96	2,505.06	3,330.89	3,204.81	3,224.8	3,290.94	2,925.46	3,247.05	3,169.17	3,437.53	4,144	- -	4,350.05
Basic Weighted Avg Shares	20	20	20	20	21	20	20	20	21	21	21	20	- -	20
Sales/Revenue/Turnover	126,768	120,461	122,426	117,637	120,684	123,310	107,681	111,122	130,395	119,746	126,583	135,373	156,463	156,463
Operating Margin (%)	-11.6	0.87	-1.16	1.78	3.29	2.08	3.05	5.01	4.63	-1.4	4.17	-1.47	4.28	4.28
Depreciation Expense	4,152	4,077	3,780	3,357	2,887	2,642	2,741	3,251	3,626	4,419	4,488	4,204	3,203	3,203
Net Income, GAAP	-18,940	2,125	-6,932	-5,943	773	1,092	2,193	-4,761	2,203	-1,559	3,557	-8,415	5,205	5,205
Effective Tax Rate (%)	- -	- -	- -	- -	54.87	49.4	22.87	4,021.09	60.77	- -	25.34	- -	21.23	21.23
Profit Margin (%)	-14.94	1.76	-5.66	-5.05	0.64	0.89	2.04	-4.28	1.69	-1.3	2.81	-6.22	3.33	3.33
Working Capital	12,629	39,226	16,354	34,521	10,506	8,960	6,360	1,884	-5,417	-6,319	680	-4,568	28,427	28,427
LT Debt	750	24,250	7,000	27,000	2,000	4,000	- -	2,256	3,792	1,620	1,196	476	27,342	27,342
Total Equity	55,352	58,329	50,853	68,459	67,519	67,778	68,698	60,954	70,499	68,588	74,079	84,950	89,548	89,548
Return on Invested Capital (%)	- -	- -	- -	- -	1.72	1.3	2.58	-226.18	2.31	- -	3.88	- -	4.56	4.56
Return on Capital (%)	- -	- -	- -	- -	2.12	2.74	5.12	-71.88	4.36	- -	7.75	- -	11.78	11.78
Return on Common Equity (%)	-43.05	5.91	-20.44	-22.06	3.24	4.49	8.85	-22.27	11.21	-7.45	15.17	-38	23.48	23.48

Year	Q1	Q2	Q3	Q4	FY
2022	33,251	32,241	30,163	30,929	126,583
2023	32,408	35,545	32,124	35,296	135,373
2024	37,534	37,643	39,651	41,635	156,463

Kukje Pharma Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Working Capital

Capital Structure

Quarterly Earnings Per Share

Year

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year